Panel configurator
Configure your own panel here
Register now
December 17, 2019
Farnell DA, Huntsman D, Bashashati A.
February 7, 2022
Alfred Hitchcock once said, “The more successful the villain, the more successful the picture”, for the immunotherapy picture, that successful villain is M1 macrophages.
Kirsty Maclean Ph.D.
Point of VUE
October 26, 2022
GEN: Typically, image analysis tools are greatly influenced by inconsistent staining results and even different techniques used for multiplexing. How does the software used by OracleBio account for inter- and intra-run variability in staining quality? Lorcan. To be honest, we do see staining variability in some sample sets, especially in complex tissues from large clinical
Lorcan Sherry Ph.D
digital pathology, multiplex image analysis, Points of VUE, tumor microenvironment
December 22, 2021
Despite advances in immunotherapy, it’s clear that only a minority of patients respond. Therapies that rely on immune activation, such as checkpoint inhibitors, have been shown to be especially difficult due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Clearly there’s much anticipation and focus on new contenders for successful combination checkpoint therapy.
GEN: If I were to design my own panel for immunofluorescence, what are the main considerations, given everything you’ve suggested during the webinar for validation? Angela: There are several things one needs to think about when you build a new panel for multiplexed immunofluorescence. You need to consider the abundance of the targets to be
Angela Vasaturo Ph.D.
immunofluorescence, spatial biology, tumor microenvironment
October 27, 2021
The brilliant Stephen Hawking once said that “The universe does not behave according to our pre-conceived ideas. It continues to surprise us.” The same statement is also true for how we think of the dynamic nature of the cancer universe, in particular the complexity of the tumor immune microenvironment (TiME/TMEs)- an ever-evolving rich milieu comprising of non-malignant immune cells, fibroblasts, adipocytes, extracellular matrix components and neuronal cell types.
March 30, 2022
Adapted from a line in “Ode to a Mouse” from fellow countryman Robert Burns, the phrase, “the best-laid plans of mice and men often go awry”, indicate that no matter how carefully a project is planned, something may still go wrong with it unfortunately speaks to the reality of clinical trials for novel therapeutics, with approximately only 11% of drugs that begin phase I clinical trials eventually being licensed.
Kirsty Maclean, Ph.D.
October 15, 2021
As I approach my one-year anniversary with Ultivue, I am excited to be part of a vibrant, rapidly growing company committed to transforming anatomic pathology with our next generation staining technology, InSituPlex®.
Keith Wharton, Jr., MD Ph.D. FCAP
September 13, 2021
I have learned in my career that there is a special recipe for making young companies successful. You need to have an amazing product that enables customers to accomplish their goals in a better way than their current method.
Jacques Corriveau